# Midodrine Versus Albumin for Prevention of Paracentesis Induced Circulatory Disturbance

> **NCT05240391** · PHASE3 · COMPLETED · sponsor: **Asian Institute of Gastroenterology, India** · enrollment: 50 (actual)

## Conditions studied

- Paracentesis-Induced Circulatory Dysfunction

## Interventions

- **DRUG:** Midodrine Hydrochloride
- **DRUG:** Human Albumin 20%

## Key facts

- **NCT ID:** NCT05240391
- **Lead sponsor:** Asian Institute of Gastroenterology, India
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-20
- **Primary completion:** 2022-05-01
- **Final completion:** 2022-05-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2022-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05240391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05240391, "Midodrine Versus Albumin for Prevention of Paracentesis Induced Circulatory Disturbance". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05240391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*